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Angiogenesis is a complex process describing the growth of new blood vessels from
existing vasculature, and is triggered by local pro-angiogenic factors, such as vascular
endothelial growth factor (VEGF), which increase the metabolism of endothelial cells
(ECs). Angiogenesis takes part in various physiological conditions such as
embryogenesis, placental growth, and in pathological conditions such as tumor growth,
diabetic retinopathy, rheumatoid arthritis (RA) and ischemic diseases. Current
therapies against excessive angiogenesis target vascular growth signaling. However,
tumors often counteract these therapies through adaptive mechanisms, thus novel
alternative anti-angiogenic strategies are needed. Targeting metabolism is a new anti-
angiogenic paradigm, especially through the inhibition of energy metabolism and
glycosylation, with the perspective of maintaining the delicate balance between the
beneficial and deleterious effects of excessive angiogenesis in patients. Recent studies
described a role for EC glycolysis and its main regulator 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in the regulation of angiogenesis, but
only few studies are related to the role of the hexosamine biosynthesis pathway during
angiogenesis. Glycosylation allows the formation of glycoproteins, glycolipids and
proteoglycans and impacts many pathways. The addition of glycans to N-linked
proteins is catalyzed by the enzymatic activity of N-acetylglucosaminyltransferases
(GnTs), which regulates the glycosylation status of key angiogenic factors such as
VEGF receptor 2 (VEGFR2) and Notch. In addition, glycan-galectin (Gal) interactions
regulate vascular signaling programs and may contribute to tumor adaptations to anti-
angiogenic strategies. Herein, we review novel pharmacological strategies targeting
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